Anticoagulant Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The ARTESIA trial showed apixaban reduced the relative hazard of stroke/systemic embolism in subclinical atrial fibrillation (SCAF; 6 min-24 hr) by 37%, but did not report absolute risk reduction (ARR). The reported Kaplan-Meier analysis and incidence rate reduction did not account for the competing risk of death or 24-hour AF events. We reanalyzed ARTESIA accounting for competing risks to determine the ARR of apixaban vs. aspirin.
Methods
Individual time-to-event and time-to-censoring data were extracted from the published Kaplan-Meier curve. ARTESIA classified deaths and 24-hour AF events as censoring events. We probabilistically reclassified them to competing events to estimate the ARR accurately. We used the Aalen-Johansen estimator to estimate the cumulative risk of stroke/systemic embolism, accounting for competing events.
Results
After reclassification of deaths and 24-hour AF to competing events, there were 1111 censoring and 852 competing events in the apixaban arm, and 1100 censoring and 816 competing events in the aspirin arm. At 6 years, the ARR was 2.09% (95% CI -0.17 to 4.34) when death and 24-hour AF events were treated as censoring events vs. 1.68% (95% CI 0.46 to 2.89) when they were treated as competing events.
Conclusion
In SCAF, apixaban reduced the 6-year risk of stroke/systemic embolism by 1.68%, a 20% lower benefit when accounting for competing risks. Accounting for competing risks is essential to accurately measure the benefit of anticoagulants for SCAF.
